Halberd Corporation Successfully Conjugates Metallic Particles and E. Coli Antibody

Breakthrough Achievement Enables Extracorporeal Eradication of Pathogens Via Radio Frequency Waves and/or Laser Emissive Energy

JACKSON CENTER, PA / ACCESSWIRE / May 25, 2021 / Halberd Corporation (OTC PINK:HALB) announces the successful conjugation of gold-coated iron nanoparticles with an available E.coli antibody. This milestone is a result of the Halberd sponsored research being conducted at GreenBioAz by Dr. Shawn Q. Chen. The conjugated E. coli antibody and metallic nanoparticle is a major step toward the eradication of numerous bacteria from bodily fluids, such as cerebral spinal fluid (CSF) or blood, when exposed to tuned radio frequency waves or laser emissive energy. The gold-coating of iron nanoparticles combines the best features of each metal for this disease eradication process.

E. coli is the second leading cause of spinal infections (meningitis) in infants and is the most likely cause of blood sepsis. Almost ¾ of a million Americans lost their lives to these diseases last year.

Dr. William G. Sturrus of Youngstown State University, will be overseeing the E. coli elimination proof-of-concept testing. Dr. Sturrus stated, “We’ve done some experimentation with iron oxide nanoparticles suspended in water, and the results showing we can elevate the temperature of the water by exposing the suspension to radio frequency waves or lasers have been very encouraging. We anticipate that the gold-coated iron oxide nanoparticles conjugated with E. coli antibodies/antigens will behave in much the same way. The experimentation we have accomplished to date is a precursor of our planned program to demonstrate the eradication of serious pathogens by radio waves and/or laser energy.”

William A. Hartman, Halberd’s Chairman, President & CEO, commented, “The cooperation and coordination between our research partners at two state universities, each with their own expertise, combined with the expertise of GreenBioAZ has produced some very promising results. E. coli is a good starting point for our testing in that it is relatively safe to work with, yet it has characteristics common to many antibiotic-resistant bacteria. Our patented extracorporeal methodology combined with radio frequency and/or laser exposure could mean the end of bacterial diseases, including antibiotic-resistant bacterial diseases. We believe our extracorporeal treatment process has the added benefit of eliminating side-effects normally associated with ingested or injected drug therapies, a long-sought-after goal of the pharmaceutical industry.”

Mr. Hartman continued “Our extensive portfolio of patent protection gives Halberd a unique position in the disease treatment industry.”

To get the latest news on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies:

Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/648903/Halberd-Corporation-Successfully-Conjugates-Metallic-Particles-and-E-Coli-Antibody